Investor · 4 deals
Every published round Monash Ventures Pre-Seed Fund took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Remagine Labs | Pre-seed | 4 Aug 2025 | $500k | Participant | @AuManufacturing (11 Aug 2025), @AuManufacturing (1 Aug 2025), Breakthrough Victoria | |
| Myostellar | Pre-seed | 4 Aug 2025 | $750k | Participant | @AuManufacturing (11 Aug 2025), Breakthrough Victoria (4 Aug 2025), @AuManufacturing (1 Aug 2025), Breakthrough Victoria (1 Aug 2025) | |
| Fyton Bio | Pre-seed | 4 Aug 2025 | $1m | Participant | @AuManufacturing (11 Aug 2025), @AuManufacturing (1 Aug 2025), Breakthrough Victoria | |
| xCystence Bio | Pre-seed | 30 Mar 2026 | - | Participant | Uniseed, Breakthrough Victoria |
Companies Monash Ventures Pre-Seed Fund has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Fyton Bio | Working on antibody therapies to target and eliminate disease-causing immune cells in aut… | 4 Aug 2025, Pre-seed | 1 | 0 |
| Myostellar | Developing a biologic therapy for Duchenne Muscular Dystrophy that promotes muscle regene… | 4 Aug 2025, Pre-seed | 1 | 0 |
| Remagine Labs | Wearable electronically controlled drug delivery device startup | 4 Aug 2025, Pre-seed | 1 | 0 |
| xCystence Bio | Victorian biotechnology company developing new treatments for polycystic kidney disease | 30 Mar 2026, Pre-seed | 1 | 0 |
Fund closes reported for Monash Ventures Pre-Seed Fund, as distinct from the investments it has made.
Companies Monash Ventures Pre-Seed Fund has backed that another company then bought. An exit for the holding, not a deal Monash Ventures Pre-Seed Fund did.
| Name | Role | Sources |
|---|---|---|
| Dr Nadine Brew | Independent Member | Startup Daily |
| Ingmar Wahlqvist | Senior Director | - |
| Vafa Shams | Independent Member | Startup Daily |
Stories naming Monash Ventures Pre-Seed Fund. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
xCystence Bio secured pre-seed funding from Uniseed, Monash Ventures, Breakthrough Victoria, and BioCurate to develop targeted protein degraders for treating genetic kidney disease.
Victorian pre-seed program BVUIP, backed by Breakthrough Victoria and seven universities, has funded startups EntroMat, Excelligent and Remagine Labs, plus fellowship grants for three PhD-led ventures.
Two Victorian backers put a combined $2.25 million into three university spinouts pursuing biologics, antibody drugs and delivery devices, launching a new $15 million pre-seed vehicle.
Also @AuManufacturing